People · Operator
Named in public records as an officer, director or promoter · active 2020–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lenz Therapeutics, Inc. | — | Biotechnology | Series C | $136.2M | $1.2B | 2020 |
| iBio, Inc. | — | Biotechnology | Series B | $74.4M | $96.5M | 2023 |
Evert Schimmelpennink at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Evert Schimmelpennink on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Clark | 1 | 12 |
| Clare Ozawa | 1 | 8 |
| James Hill | 1 | 6 |
| Mark - Lester | 1 | 6 |
| Zach Scheiner | 1 | 6 |
| ROBERT KAY | 1 | 4 |
| Stefan Larson | 1 | 4 |
| Robert Erwin | 1 | 4 |
| James McCollum | 1 | 3 |
| Gary Sender | 1 | 3 |
| CHRIS DIMITROPOULOS | 1 | 3 |
| Frederic Guerard | 1 | 2 |
| David A Arkowitz | 1 | 2 |
| Gary A. Sender | 1 | 2 |
| Philip Russell | 1 | 1 |
| Arthur Elliott | 1 | 1 |
| Mark Giannone | 1 | 1 |
| GLENN CHANG | 1 | 1 |
| Terence Ryan | 1 | 1 |
| PAMELA K. BASSETT | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.